Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tetra Bio Pharma Inc (TSX: TBP ) N/A UNCHANGED Last Price Updated: 3:59 PM EST, Mar 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tetra Bio Pharma Inc Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003 March 03, 2023 The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral... Via TheNewswire.com Exposures COVID-19 Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis March 01, 2023 MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and... Via TheNewswire.com The Power Play by The Market Herald Releases New Interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold Discussing Their Latest News November 30, 2022 Via ACCESSWIRE Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug July 12, 2022 From Akanda Corp. and Tetra Bio-Pharma Via Business Wire Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021 December 06, 2021 LOS ANGELES, CA / ACCESSWIRE / December 6, 2021 / The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will... From Stock News Now Via AccessWire Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting June 02, 2021 This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 - The... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain May 11, 2021 First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial May 06, 2021 First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 /... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios May 05, 2021 This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals May 04, 2021 A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures COVID-19 Cannabis Intellectual Property Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada May 03, 2021 The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra"... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority April 28, 2021 Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in... From Tetra Bio-Pharma Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial April 23, 2021 - First clinical study to assess cannabis as an alternative to morphine - Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial - Export permit received from Health Canada for... From Tetra Bio-Pharma Via AccessWire Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Product Safety Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis April 15, 2021 - Tetra strengthens its intellectual property portfolio - Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc.... From Tetra Bio-Pharma Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada April 14, 2021 - REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug - The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 /... From Tetra Bio-Pharma Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.